Search

Displaying results 861 - 870 of 4262 in total
  1. Drug

    Cannabidiol

    go.drugbank.com/drugs/DB09061
    ApprovedInvestigational

    On June 25th, 2018, Epidiolex was approved by the FDA to be the first CBD-based product available on the US market. … Cannabinoid receptors are utilized endogenously by the body through the endocannabinoid system, which includes a group of lipid proteins, enzymes, and receptors that are involved in many physiological

  2. Drug

    Artenimol

    go.drugbank.com/drugs/DB11638
    ApprovedInvestigational

    Artemisinin combination therapy is highly effective against malaria and stongly recommended by the World Health Organization [L1156]. … It was first authorized for market by the European Medicines Agency in October 2011 in combination with [DB13941] as the product Eurartesim.

  3. Drug

    Interferon alfa-n1

    go.drugbank.com/drugs/DB00011
    ApprovedWithdrawn

    Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produc...

  4. Drug

    Eptinezumab

    go.drugbank.com/drugs/DB14040
    ApprovedInvestigational

    Eptinezumab is a fully-humanized IgG1 antibody manufactured using yeast (_Pichia pastoris_) and developed by Lundbeck Seattle Biopharmaceuticals. … [F94,A33105,A33106,A33108] It was approved by the FDA in February 2020 for the preventive treatment of migraine headaches in adults.[L12318]

  5. Drug

    Fluocinolone acetonide

    go.drugbank.com/drugs/DB00591
    ApprovedInvestigationalVet approved

    [T358] This type of device containing fluocinolone acetonide was developed by Taro Pharmaceuticals and approved by FDA in May 2016.[L4676]

  6. Drug

    Aficamten

    go.drugbank.com/drugs/DB18490
    ApprovedInvestigational

    [L54783] Aficamten works by attenuating myocardial hypercontractility and left ventricular outflow tract obstruction, which are characteristics of oHCM.[A275293] … [L54788] Approved by the FDA on December 19, 2025, aficamten is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and

  7. Drug

    Pancrelipase amylase

    go.drugbank.com/drugs/DB11065
    ApprovedInvestigational

    [L2509] The amylases are enzymes that help in the chemical process of digestion by hydrolizing starch into more available saccharide forms. … [L2512] The pancrelipase mixture, including pancrelipase amylase, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510]

  8. Drug

    Hydrochlorothiazide

    go.drugbank.com/drugs/DB00999
    ApprovedInvestigationalVet approved

    [A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors.

  9. Drug

    Natalizumab

    go.drugbank.com/drugs/DB00108
    ApprovedInvestigational

    [A261331] On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA.[L48041] Natalizumab was approved by the European Commission on September 22, 2023. … [A261326] Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008.

  10. Drug

    Glecaprevir

    go.drugbank.com/drugs/DB13879
    ApprovedInvestigational

    Mavyret is also indicated for HCV genotype 1-infected patients who have been previously treated with regimens either containing an NS5A inhibitor or an NS3/4A protease inhibitor, but not both [L940].